The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AILERON THERAPEUTICS INC | COM | 00887A105 | 647 | 517,558 | SH | SOLE | 517,558 | 0 | 0 | ||
| APELLIS PHARMACEUTICALS INC | COM | 03753U106 | 67,306 | 1,064,962 | SH | SOLE | 1,064,962 | 0 | 0 | ||
| ATEA PHARMACEUTICALS INC | COM | 04683R106 | 37,490 | 1,745,331 | SH | SOLE | 1,745,331 | 0 | 0 | ||
| BELLICUM PHARMACEUTICALS INC | COM NEW | 079481404 | 85 | 25,651 | SH | SOLE | 25,651 | 0 | 0 | ||
| CLEARSIDE BIOMEDICAL INC | COM | 185063104 | 1,430 | 293,555 | SH | SOLE | 293,555 | 0 | 0 | ||
| KEZAR LIFE SCIENCES INC | COM | 49372L100 | 700 | 128,916 | SH | SOLE | 128,916 | 0 | 0 | ||
| KYMERA THERAPEUTICS INC | COM | 501575104 | 30,994 | 639,059 | SH | SOLE | 639,059 | 0 | 0 | ||
| MOLECULAR TEMPLATES INC | COM | 608550109 | 1,602 | 204,809 | SH | SOLE | 204,809 | 0 | 0 | ||
| RAPT THERAPEUTICS INC | COM | 75382E109 | 3,163 | 99,503 | SH | SOLE | 99,503 | 0 | 0 | ||
| SEER INC | COM CL A | 81578P106 | 26,761 | 816,375 | SH | SOLE | 816,375 | 0 | 0 | ||
| SUTRO BIOPHARMA INC | COM | 869367102 | 3,253 | 175,000 | SH | SOLE | 175,000 | 0 | 0 | ||